Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
The WAVEsystem with the WAVEcontrol 4.0 embedded
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.
Subscribe To Our Newsletter & Stay Updated